Pfizer reported impressive financial results for the first quarter of fiscal 2024-2025, leading to a surge in its share price. The company’s net profit and revenue saw significant increases, reflecting strong performance and operational efficiency.
Key Financial Highlights:
– Net Profit: Pfizer’s net profit soared by 61.2% year-on-year, reaching ₹150.7 crore for the quarter ended June 30, 2024. This is a substantial rise from ₹94 crore reported in the same quarter last year.
– Revenue: Revenue from operations grew by 5.9% to ₹563 crore, compared to ₹531.4 crore in the previous fiscal period.
– EBITDA: Operating income (EBITDA) jumped 60.2% to ₹177.5 crore. The EBITDA margin improved to 31.5%, up from 20.9% in the corresponding quarter last year.
Financial Summary:
|
Metric |
Q1 FY 2024-25 |
Q1 FY 2023-24 |
Change (%) |
|
Net Profit (₹ crore) |
150.7 |
94 |
61.2% |
|
Revenue (₹ crore) |
563 |
531.4 |
5.9% |
|
EBITDA (₹ crore) |
177.5 |
110.8 |
60.2% |
|
EBITDA Margin (%) |
31.5 |
20.9 |
– |
Market Performance:
– Share Price Movement: As of 9:45 AM, Pfizer’s shares were trading 3.06% higher at ₹5,532.15 on the NSE.
Management Commentary:
Pfizer’s robust Q1 results highlight the company’s effective strategies and operational improvements. The significant profit and revenue growth underscores Pfizer’s strong position in the pharmaceutical sector.
